# Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

> **NCT06571942** · PHASE4 · RECRUITING · sponsor: **National Institute of Respiratory Diseases, Mexico** · enrollment: 128 (estimated)

## Conditions studied

- COPD Bronchitis
- Pollution Related Respiratory Disorder

## Interventions

- **DRUG:** Vilanterol / Umeclidinium (25/62.5 mcg)
- **DRUG:** Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)
- **DRUG:** Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg
- **DRUG:** Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg

## Key facts

- **NCT ID:** NCT06571942
- **Lead sponsor:** National Institute of Respiratory Diseases, Mexico
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-15
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06571942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06571942, "Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06571942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*